Celularity (NASDAQ:CELU) versus Exicure (NASDAQ:XCUR) Head-To-Head Review

Celularity (NASDAQ:CELU) and Exicure (NASDAQ:XCUR) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.

Valuation & Earnings

This table compares Celularity and Exicure”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celularity	$26.55 million	1.50	-$91.72 million	($3.33)	-0.41
Exicure	$500,000.00	15.85	-$4.95 million	($1.32)	-0.92

Exicure has lower revenue, but higher earnings than Celularity. Exicure is trading at a lower price-to-earnings ratio than Celularity, indicating that it is currently the more affordable of the two stocks.

Insider & Institutional Ownership

19.0% of Celularity shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 17.3% of Celularity shares are held by company insiders. Comparatively, 52.8% of Exicure shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Risk and Volatility

Celularity has a beta of 0.79, indicating that its stock price is 21% less volatile than the S&P 500. Comparatively, Exicure has a beta of 3.63, indicating that its stock price is 263% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Celularity and Exicure, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celularity	1	0	0	0	1.00
Exicure	1	0	0	0	1.00

Profitability

This table compares Celularity and Exicure’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Celularity	-345.45%	N/A	-77.94%
Exicure	N/A	-237.91%	-61.98%

Summary

Exicure beats Celularity on 8 of the 11 factors compared between the two stocks.

About Celularity

Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, an allogeneic CAR-T cell for the treatment of non-Hodkin's lymphoma (NHL) and mantle cell lymphoma (MCL); CYNK-001, an allogeneic unmodified natural killer cell that is in Phase I/II clinical trial for the treatment of acute myeloid leukemia (AML); and APPL-001, a genetically modified placental-derived mesenchymal-like adherent stromal cell for the treatment of Crohn's disease. It is also developing CYCART-201 for the treatment of NHL and MCL, and human epidermal growth factor receptor 2 positive cancers; CYNK-301, a next generation chimeric antigen receptor-natural killer (CAR-NK) for treating relapse refractory AML; CYNK-302, a CAR-NK to treat non-small cell lung cancer; and pExo-001, a human postpartum placenta derived exosome product for the treatment of osteoarthritis. It also produces, sells, and licenses products that are used in surgical and wound care markets, such as Biovance, Biovance 3L, Interfyl, and Centaflex; and collects and stores stem cells from umbilical cords and placentas under the LifebankUSA brand. The company has licensing agreement with Sorrento Therapeutics, Inc. for the development and commercialization of licensed CD19 CAR-T products; and research collaboration services agreement with Regeneron Pharmaceuticals, Inc. to support the research of allogeneic cell therapy candidates. The company was founded in 1998 and is based in Florham Park, New Jersey.

About Exicure

Exicure, Inc., an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.